Beam Therapeutics Inc. — FY2020 Form 10-K Summary
Business context and reporting period
Beam Therapeutics is an early-stage biotechnology company developing precision genetic medicines based primarily on proprietary base-editing technology. The filing covers the fiscal year ended December 31, 2020; it is an annual report rather than a quarterly filing. All programs remained in research or preclinical development, with no product approved or generating product sales.
- Lead programs included BEAM-101 and BEAM-102 for sickle cell disease and beta-thalassemia, BEAM-201 for T-cell acute lymphoblastic leukemia, liver programs for alpha-1 antitrypsin deficiency and glycogen storage disease type Ia, and an ocular program for Stargardt disease.
- The company operated one segment, primarily in the United States, and had 181 full-time employees at year-end, including 149 in research and development.
Financial performance, cash flow, liquidity and obligations
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| License revenue | $24 thousand | $18 thousand | +$6 thousand |
| Research and development expense | $103.2 million | $54.6 million | +$48.6 million |
| General and administrative expense | $29.6 million | $20.6 million | +$9.1 million |
| Loss from operations | $(132.8) million | $(75.2) million | $(57.6) million |
| Net loss | $(194.6) million | $(78.3) million | $(116.3) million |
| Net loss attributable to common stockholders | $(195.9) million | $(91.0) million | $(104.8) million |
| Basic and diluted loss per share | $(4.19) | $(14.05) | Improved due primarily to a larger share base |
| Net cash used in operating activities | $(95.7) million | $(72.0) million | $(23.7) million |
| Net cash used in investing activities | $(100.1) million | $(66.7) million | $(33.5) million |
| Net cash provided by financing activities | $322.3 million | $41.3 million | +$281.0 million |
- License revenue was immaterial and represented amortization of consideration under the Verve collaboration; the company does not expect product revenue for the foreseeable future.
- Operating expenses increased substantially as Beam expanded preclinical work, outsourced research and manufacturing, staffing, facilities and platform development.
- The net loss included a $63.4 million non-cash expense from revaluation of Harvard and Broad Institute success-payment liabilities, compared with $5.4 million in 2019.
- Cash, cash equivalents and marketable securities totaled $299.7 million at December 31, 2020. Cash, cash equivalents and restricted cash totaled $177.0 million.
- Debt was limited primarily to equipment-financing liabilities of $7.4 million at year-end. Total liabilities were $206.1 million, including $71.2 million of current derivative liabilities and $100.2 million of operating lease liabilities.
- Contractual obligations included $169.3 million of undiscounted operating lease payments and $7.9 million of equipment-financing payments. Additional lease commitments for the MIT facility and North Carolina manufacturing facility were excluded from the principal table.
- Management stated that year-end cash, cash equivalents and marketable securities were expected to fund operations and capital expenditures for at least 12 months, but additional financing will be required to support the development plan.
Material changes versus the prior comparable period
- Beam completed its initial public offering in February 2020, receiving approximately $188.3 million in net proceeds, and completed an October 2020 public offering, receiving approximately $126.6 million in net proceeds.
- All redeemable convertible preferred stock converted into common stock upon the IPO. Year-end common shares outstanding increased to approximately 57.3 million from 7.3 million at December 31, 2019.
- Research and development expense increased 89%, driven by outsourced services and laboratory supplies, IND-enabling work, license and milestone expenses, personnel, facilities and stock-based compensation.
- General and administrative expense increased 44%, reflecting higher public-company insurance, personnel, information technology, intellectual-property and stock-based compensation costs.
- Capital spending increased to $16.4 million from $12.5 million, while property and equipment increased to $38.5 million from $24.3 million.
- Beam entered into a lease to build a 100,000-square-foot cGMP manufacturing facility in North Carolina. The company expects to invest up to $83.0 million over five years and expects the facility to be operational by the first quarter of 2023.
- Preclinical progress included advancement of BEAM-101 toward an anticipated IND filing in the second half of 2021, planned IND-enabling studies for BEAM-102 and BEAM-201 in 2021, and planned selection of a first liver development candidate in the second half of 2021.
Guidance, outlook, commentary and risks
- Management expects continued and increasing operating losses, negative operating cash flow and substantial research, development, manufacturing, regulatory and public-company expenses.
- Management expected initial non-human-primate data evaluating the LNP formulation in the first half of 2021 and anticipated an IND filing for BEAM-101 in the second half of 2021. These are targets, not assurances of achievement.
- Beam expects to rely on third-party manufacturers for initial clinical programs while developing internal manufacturing capacity.
- The first success-payment measurement under the Harvard and Broad license agreements was expected in May 2021. The related liabilities totaled $71.2 million at year-end and could affect cash resources if settled in cash, although Beam may elect to settle in common stock.
- After year-end, Beam raised $252.1 million in net proceeds through a January 2021 private placement. In February 2021, it agreed to acquire Guide Therapeutics for $120.0 million of upfront stock consideration, with up to $320.0 million of additional stock-based technology and product-success milestones.
- Key risks include the lack of clinical validation for base editing, potential off-target or delayed effects from permanent genetic edits, uncertain regulatory requirements, clinical and manufacturing failure, dependence on third-party suppliers, intellectual-property disputes and license obligations, competition, patient enrollment challenges, future capital needs and COVID-19-related disruptions.
- The filing notes a potential 5 kilobase deletion in the BEAM-101 target region observed in certain studies; Beam was conducting additional studies to determine its frequency and potential significance.
- COVID-19 did not significantly affect 2020 results, but continued restrictions, supply-chain disruptions, facility access limitations and delays to preclinical or future clinical work could materially affect future performance.
Most important facts for investors to verify
- Whether BEAM-101 enters clinical development and whether the anticipated IND filing occurs on schedule.
- Whether preclinical efficacy, safety, off-target and deletion findings translate into acceptable human clinical results.
- The pace and cost of advancing BEAM-102, BEAM-201 and liver programs toward IND-enabling studies and clinical trials.
- Remaining cash runway after the January 2021 financing, the Guide acquisition and planned manufacturing investment, including the potential cash settlement of success-payment liabilities.
- Construction progress, total cost and operational readiness of the North Carolina manufacturing facility and the new Cambridge facility.
- Resolution of patent interference, opposition, ownership and licensing issues affecting CRISPR and base-editing rights.
- Future dilution from equity financings, stock-based compensation, license obligations, Guide milestones and potential settlement of success payments in common stock.